Replimune Group, Inc. - Common Stock (NQ:REPL)

2.025 +0.075 (+3.85%)

Streaming Delayed Price Updated: 9:51 AM EDT, Apr 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Replimune Group, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

The trading volume of these stocks is deviating from the norm in today's session. ↗

April 14, 2026

On Tuesday, there are stocks with unusual volume. Let's take a look.

Via Chartmill

Topics Artificial Intelligence

Which stocks are moving on Monday? ↗

April 13, 2026

Here are the top movers in Monday's session, showcasing the stocks with significant price changes.

Via Chartmill

What's going on in today's session ↗

April 13, 2026

Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

What Is Driving Replimune Stock’s 98% Surge Today? ↗

October 20, 2025

Via Stocktwits

These stocks are gapping in today's session ↗

April 13, 2026

Let's have a look at what is happening on the US markets on Monday. Below you can find the gap up and gap down stocks in today's session.

Via Chartmill

Which stocks are moving before the opening bell on Monday? ↗

April 13, 2026

Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

April 10, 2026

From Replimune, Inc.

Via GlobeNewswire

Replimune to Present at Two Upcoming Investor Conferences

March 02, 2026

From Replimune, Inc.

Via GlobeNewswire

Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

February 03, 2026

April 10, 2026 Target Action Date for RP1 in Advanced Melanoma

From Replimune, Inc.

Via GlobeNewswire

Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 18, 2025

From Replimune, Inc.

Via GlobeNewswire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 14, 2025

Via Benzinga

These stocks are moving in today's after hours session ↗

November 11, 2025

The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Via Chartmill

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

November 07, 2025

Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade in advanced melanoma following definitive anti-PD-1 failure

From Replimune, Inc.

Via GlobeNewswire

Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

November 06, 2025

From Replimune, Inc.

Via GlobeNewswire

Kimberly-Clark, Vertex And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

November 03, 2025

Via Benzinga

This Five Below Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗

October 27, 2025

Via Benzinga

The Best AI for Picking Stocks, Ranked by Performance ↗

October 22, 2025

AI can pick stocks, but that doesn't mean it will do a good job. Here's a look at how the choices made by 7 leading AIs performed over a 90-day time period.

Via MarketBeat

Topics Artificial Intelligence ETFs

Why Replimune Stock Was Soaring Today ↗

October 20, 2025

An investigational treatment, used in combination with another cancer medication, took an important step forward after several setbacks.

Via The Motley Fool

These stocks are moving in today's session ↗

October 20, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 20, 2025

Via Benzinga

These stocks are the most active in today's session ↗

October 20, 2025

Let's dive into the action on the US markets on Monday. Here are the most active stocks that are driving the market today.

Via Chartmill

Top movers analysis in the middle of the day on 2025-10-20: top gainers and losers in today's session. ↗

October 20, 2025

Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

Here's Why Replimune Group (REPL) Stock Is Up Over 100% Today ↗

October 20, 2025

Shares of Replimune Group are rising Monday after the clinical stage biotechnology company shared an important regulatory update.

Via Benzinga

Gapping stocks in Monday's session ↗

October 20, 2025

Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday ↗

October 20, 2025

Via Benzinga

Topics Artificial Intelligence

Dow Jumps Over 200 Points; Cleveland-Cliffs Shares Jump After Q3 Results ↗

October 20, 2025

Via Benzinga

Topics Stocks

These stocks are moving in today's pre-market session ↗

October 20, 2025

As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

October 20, 2025

Via Benzinga

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

October 20, 2025

Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026

From Replimune, Inc.

Via GlobeNewswire

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

October 19, 2025

From Replimune, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.